PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Cost reduction while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
12.50%
Growth of 12.50% while AVXL shows flat gross profit. Bruce Berkowitz would examine quality advantage.
No Data
No Data available this quarter, please select a different quarter.
37.48%
R&D growth above 1.5x AVXL's 12.03%. Michael Burry would check for spending discipline.
21.30%
G&A growth above 1.5x AVXL's 6.94%. Michael Burry would check for operational inefficiency.
100.00%
Marketing expense change of 100.00% while AVXL maintains spending. Bruce Berkowitz would investigate effectiveness.
No Data
No Data available this quarter, please select a different quarter.
32.37%
Operating expenses growth above 1.5x AVXL's 10.86%. Michael Burry would check for inefficiency.
29.39%
Total costs growth above 1.5x AVXL's 10.86%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
D&A reduction while AVXL shows 12.58% growth. Joel Greenblatt would examine efficiency.
-30.36%
EBITDA decline while AVXL shows 100.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-29.39%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
14.89%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
-30.95%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing tax expense. Martin Whitman would check patterns.
-30.95%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.58%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-22.58%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
7.95%
Share count reduction below 50% of AVXL's 0.47%. Michael Burry would check for concerns.
7.95%
Diluted share reduction below 50% of AVXL's 0.47%. Michael Burry would check for concerns.